Allergan Inc (AGN.N)

AGN.N on New York Stock Exchange

98.02USD
24 May 2013
Price Change (% chg)

$0.06 (+0.06%)
Prev Close
$97.96
Open
$97.58
Day's High
$98.57
Day's Low
$96.89
Volume
587,503
Avg. Vol
454,161
52-wk High
$116.44
52-wk Low
$81.28

AGN.N

Chart for AGN.N

About

Allergan, Inc., is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. The Company operates in two segments: specialty pharmaceuticals and medical devices. On June 17, 2011, it acquired Alacer Biomedical, Inc. (Alacer). On... (more)

Overall

Beta: 0.81
Market Cap (Mil.): $29,053.17
Shares Outstanding (Mil.): 296.40
Dividend: 0.05
Yield (%): 0.20

Financials

  AGN.N Industry Sector
P/E (TTM): 26.22 34.14 34.28
EPS (TTM): 3.74 -- --
ROI: 14.42 19.49 18.85
ROE: 21.09 20.26 19.72
Search Stocks

Allergan delays drug that would rival Regeneron's Eylea

- Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea, stands to gain from a lack of new competition.

01 May 2013

UPDATE 3-Allergan delays drug that would rival Regeneron's Eylea

May 1 - Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea, stands to gain from a lack of new competition.

01 May 2013

Allergan delays eye drug, shares fall

- Allergan Inc , maker of the Botox anti-wrinkle treatment, said it will delay late-stage trials of its highly anticipated eye drug Darpin, sending its shares down 14 percent.

01 May 2013

BRIEF-Regeneron Pharma shares resume trading, up 16 percent

NEW YORK, May 1 - Regeneron Pharmaceuticals Inc : * Shares resume trading, up 16 percent * Shares as shares of Allergan slide after co says vision drug approval

01 May 2013

BRIEF-Allergan resumes trading down 11.5 percent after company says phase 2 eye drug data does not support directly moving to phase 3

NEW YORK, May 1 - Allergan Inc : * Resumes trading down 11.5 percent after company says phase 2 Darpin eye drug data does not support directly moving to phase 3

01 May 2013

Strong Botox sales boost Allergan profit

- Allergan Inc , maker of the Botox anti-wrinkle treatment, posted a stronger-than-expected quarterly profit, helped by strong sales of its eye-care drugs and Botox, which was recently also approved for treating migraine headaches.

01 May 2013

Strong Botox sales boost Allergan profit

May 1 - Allergan Inc, maker of the Botox anti-wrinkle treatment, posted a stronger-than-expected quarterly profit, helped by strong sales of its eye-care drugs and Botox, which was recently also approved for treating migraine headaches.

01 May 2013

FDA staff says Allergan's new dermal filler effective

April 30 - Reviewers for the U.S. Food and Drug Administration said Allergan Inc's dermal filler, Juvéderm Voluma XC, was effective in correcting volume deficit in the middle of the face at six months of treatment.

30 Apr 2013

Fraudulent versions of Allergan's Botox found in U.S.

- Fraudulent versions of the wrinkle treatment Botox, which is made by Allergan Inc and also used to treat headaches, underarm sweating and overactive bladder, are being sold in the United States, the Food and Drug Administration said on Friday.

26 Apr 2013

UPDATE 3-Fraudulent versions of Allergan's Botox found in U.S.

April 26 - Fraudulent versions of the wrinkle treatment Botox, which is made by Allergan Inc and also used to treat headaches, underarm sweating and overactive bladder, are being sold in the United States, the Food and Drug Administration said on Friday.

26 Apr 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$58.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Jefferson Research
$20.00
Provider: S&P Capital IQ – STARS Reports
$115.00
Provider: Plunkett Research, Ltd.
$99.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks